This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer
BMC Cancer Open Access 24 April 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30445-9 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. TMB — a histology-agnostic predictor of the efficacy of ICIs?. Nat Rev Clin Oncol 17, 718 (2020). https://doi.org/10.1038/s41571-020-00438-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-00438-0